In like a lion, out like a lion: The Tipline for 12 October 2021

Rohit Chopra has left the Federal Trade Commission, but not before taking one final shot at the agency’s antitrust record. In his final statement as commissioner, the progressive firebrand said the merger remedies study published by the commission in 2017 greatly exaggerated the effectiveness of divestitures the FTC required for several pharmaceutical deals. “I believe the study should not be cited by the public going forward,” Chopra said, without specifying what he viewed as the study’s deficiencies.

Get unlimited access to all Global Competition Review content